Nexium (Esomeprazole Magnesium Trihydrate)

Esomeprazole, the active ingredient in Nexium, is a proton pump inhibitor presented as an oral formulation for oral use. It reduces gastric acid secretion and is employed in the management of acid‑related disorders such as gastro‑oesophageal reflux disease and peptic ulcer disease. Nexium is indicated for adult patients who require potent acid suppression.

GNH USA supplies Nexium as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nexium is a proton pump inhibitor used to treat conditions caused by excess gastric acid.

- Gastro‑oesophageal reflux disease (GERD): reduces acid exposure, relieving heartburn and regurgitation. - Erosive esophagitis: promotes healing of acid‑induced esophageal lesions. - Peptic ulcer disease: supports ulcer healing and prevents recurrence. - Helicobacter pylori eradication: used in combination therapy to increase eradication rates. - Zollinger‑Ellison syndrome: controls hyper‑secretion of gastric acid in this rare endocrine disorder.

Adverse reactions may occur with any medication and should be monitored.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: usually transient. - Nausea: may occur after dosing. - Abdominal pain: discomfort in the stomach area. - Flatulence: increased gas production. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis risk. - Severe allergic reactions: including anaphylaxis. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Elevated liver enzymes: indicating hepatic stress. - Hypomagnesemia: low serum magnesium with prolonged use. - Increased risk of bone fractures: with long‑term therapy.

Before initiating therapy, consider the following safety measures.

- Assess renal function: adjust use in severe impairment. - Monitor magnesium levels: especially during extended treatment. - Use caution in hepatic disease: dose may need adjustment. - Limit duration: avoid unnecessary long‑term use. - Evaluate osteoporosis risk: consider bone health in chronic users. - Store at room temperature: keep in the original container, protect from moisture and heat.

Esomeprazole may affect the plasma concentrations of several co‑administered drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, increasing cardiovascular risk. - Atazanavir: decreased absorption, leading to sub‑therapeutic levels. - Warfarin: unpredictable INR changes, requiring close monitoring.

Moderate Interactions (Monitor Closely): - Digoxin: increased serum concentrations. - Methotrexate: reduced clearance, risk of toxicity. - Ketoconazole: decreased absorption, may reduce antifungal efficacy. - Rifampin: induces metabolism, lowering esomeprazole levels.